<DOC>
	<DOCNO>NCT00042380</DOCNO>
	<brief_summary>The purpose study find soy-based dietary supplement Novasoy ( Registered Trademark ) effective short-term treatment clinical depression . This study also evaluate whether Novasoy ( Registered Trademark ) effective treat anxiety often accompany depression ass best dose level . Novasoy ( Registered Trademark ) market botanical dietary supplement contain soy isoflavones . The active form soy isoflavone genistin may novel treatment neuropsychiatric illness . The soy isoflavone 's specific hormonal property may also beneficial effect brain function depress patient . This study conduct two phase . During Phase I , participant stop medication least 1 week . A psychiatric medical examination conduct . During Phase II , participant randomly assign receive either Novasoy ( Registered Trademark ) placebo ( inactive pill ) 8 week . Participants respond treatment 5 week give high dose assign medication . After 8-week period , participant monitor 3 month refer back clinician treatment .</brief_summary>
	<brief_title>Examination Soy-Based Supplement Major Depression</brief_title>
	<detailed_description>Recurrent mood disorder devastate long-term effect , cost illness term human suffering , productivity health care enormous . It recognize , many patient , long-term outcome often much less favorable previously think , incomplete inter-episode recovery , progressive decline overall functioning observe . Indeed , accord Global Burden Disease Study , mood disorder among leading cause disability worldwide , likely represent increasingly great health , societal , economic problem come year . Dietary nutritionally derive botanical compound offer promise experimental therapeutic complex disease chemoprevention illnesses depression . Genistein polyphenolic molecule active form soy isoflavone , genistin . It phytoestrogen protein tyrosine kinase inhibit property . Since tyrosine phosphorylation involve central nervous system regulation neurotransmission inhibition genistein may novel strategy directly modulate synaptic activity treat neuropsychiatric illness . Genistein 's specific hormonal property may also salutary effect brain function depress patient . Genistein increase dopamine monoamine activity , affect neurotrophic factor transcription , neuroprotective property . This 8-week double blind parallel study examine efficacy safety Novasoy® ( Registered Trademark ) ( CAS 446-72-0 ) , market botanical dietary supplement , acutely depressed male female patient ( n &amp; eq ; 60 group ) . The study two Periods . Study Period I washout phase ( 1 week ) evaluation period . Study Period II monotherapy 8-week parallel , placebo control , acute treatment phase efficacy tolerability isoflavones compare baseline . After complete 8-week study period , subject follow mood disorder clinic NIMH necessary treatment adjustment refer back clinician treatment . Patients , age 18 , diagnosis major depression ( without psychotic feature ) , titrate onto isoflavone mixture , Novasoy® ( Registered Trademark ) , specific target dose ( genistin &amp; eq ; 270mg/day divide dos ) . At end week 5 nonresponders ( less equal 50 % improvement ) one titration high dose ( genistin &amp; eq ; 360 mg/day divide dos ) . Primary efficacy determine demonstrate great response rate use well-validated rating scale . Subjects randomize 1:1 stratification sex . Improvement depressive symptom hypothesize significantly great active soy isoflavone group .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<criteria>INCLUSION CRITERIA : Subjects may include study meet follow criterion : Male female subject , 18 old . Female subject childbearing potential must use medically accept mean contraception define one following : ) A barrier method contraception . A barrier method contraception physical barrier design prevent pregnancy , i.e. , contraceptive foam suppository , spermicide , condom , diaphragm . b ) Oral contraceptive , estrogen/progesteronebased progesterone base . Women childbearing potential also must negative serum betaHCG prestudy . Each subject must level understanding sufficient agree test examination require protocol . Each subject must understand nature study must sign informed consent document . Subjects must fulfill criterion major depression without psychotic feature define DSMIV base clinical assessment confirm structured diagnostic interview SCIDP . Subjects must score Visit 1 Visit 2 least 20 MADRS ( within 20 % ) CGIS great equal 3 . EXCLUSION CRITERIA : Participation clinical trial another investigational drug within 1 month ( 30 day ) prior study entry ( Visit 1 ) . Female subject either pregnant nursing . Patients initiate hormonal treatment ( e.g. , estrogen ) last 3 month mood , perimenopausal , menstrual symptom ( OCP birth control acceptable start last 2 month ) . Women age 4055 irregular period , last menstrual period within last 12 month , AND laboratory evidence confirm possible perimenopause , FSH great 14 IU/L . Serious , unstable illness include hepatic , renal , gastroenterologic , respiratory , cardiovascular ( include ischemic heart disease ) , endocrinologic , neurologic , immunologic , hematologic disease . History malignancy neoplastic disorder . Any present past history breast carcinoma , woman family history following : premenopausal breast cancer bilateral breast cancer firstdegree relative ; multiple family member ( great 3 relative ) postmenopausal breast cancer . History porphyria . History pulmonary embolus thrombophlebitis . Women history endometriosis , pelvic lesion , ovarian enlargement , abnormal vaginal bleeding . Subjects uncorrected hypothyroidism hyperthyroidism . Subjects one seizures without clear resolve etiology . Documented history hypersensitivity soy product . DSMIV substance abuse ( except nicotine caffeine ) within past 90 day substance dependence within past 12 month . Treatment reversible monoamine oxidase inhibitor , guanethidine , guanadrel within 2 week prior Visit 2 . Treatment fluoxetine within 2 week prior Visit 2 . Treatment concomitant medication primarily CNS activity , specify Appendix . Current diagnosis schizophrenia psychotic disorder define DSMIV . Known allergy soy soy constituent . Judged suicidal risk base use HAMD suicide item great equal 3 . Patients allow receive new course structure psychotherapy trial . Patients exclude previously fail great 3 antidepressant trial ATHF criterion . Patients exclude ECT past 12 week .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2005</verification_date>
	<keyword>Antidepressant</keyword>
	<keyword>Anxiety</keyword>
	<keyword>Dopamine</keyword>
	<keyword>Tyrosine Kinase Inhibitor</keyword>
	<keyword>Affective Disorder</keyword>
	<keyword>Phytoestrogen</keyword>
	<keyword>Genistein</keyword>
	<keyword>Major Depression</keyword>
	<keyword>Depression</keyword>
</DOC>